IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

This study is comparing two pre-surgery (neoadjuvant) treatment combinations — one using a new drug called IBI363 with chemotherapy and another using pembrolizumab (an established immunotherapy) with chemotherapy — to shrink tumors before surgery in people with resectable non-small cell lung cancer. **You may be eligible if...** - You are 18–75 years old - You have confirmed non-squamous non-small cell lung cancer (NSCLC), stage IB through IIIB - You have not yet received any treatment for your lung cancer - You are able to undergo surgery **You may NOT be eligible if...** - You have previously received cancer treatment for your lung cancer - Your cancer has spread to the brain or other distant sites - You have serious autoimmune conditions or have had severe reactions to immunotherapy before - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.